Clinical Trials Logo
  1. Home
  2. Salivary Gland Cancer
  3. NCT06091878

Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers — INDAGA-UK  

Salivary Gland Cancer Clinical Trial

Official title:
Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers: The INDAGA-UK Trial

Clinical Trial Summary

The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06091878
Study type Observational
Source Royal Marsden NHS Foundation Trust
Contact Pablo Jimenez
Phone 02073528171
Email pablo.jimenez@rmh.nhs.uk
Status Not yet recruiting
Phase
Start date March 1, 2024
Completion date January 31, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03729297 - Cabozantinib in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT01969578 - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Phase 2
Completed NCT01703455 - Activity of Sorafenib in Salivary Gland Cancer Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Suspended NCT03781986 - APG-115 in Salivary Gland Cancer Trial Phase 1/Phase 2
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05483374 - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT03172624 - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Phase 2
Completed NCT00509002 - Iressa Study in Patients With Salivary Gland Cancer Phase 2
Active, not recruiting NCT05008237 - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study Phase 2
Recruiting NCT03360890 - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Phase 2
Not yet recruiting NCT05898373 - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC Phase 1/Phase 2
Active, not recruiting NCT02069730 - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes N/A
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Completed NCT01344356 - Stereotactic Body Radiotherapy for Head and Neck Tumors Phase 4
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2